Cargando…

Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler

PURPOSE: The Respimat is a handheld, propellant-free, soft-mist inhaler. Observations by patients and physicians prompted development of an improved second-generation Respimat inhaler. Human-factor studies assessing the usability of the new inhaler and in vitro assessment of aerosol performance are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhand, Rajiv, Eicher, Joachim, Hänsel, Michaela, Jost, Ingeborg, Meisenheimer, Martin, Wachtel, Herbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407979/ https://www.ncbi.nlm.nih.gov/pubmed/30880941 http://dx.doi.org/10.2147/COPD.S190639

Ejemplares similares

Reduced Environmental Impact of the Reusable Respimat(®) Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
por: Hänsel, Michaela, et al.
Publicado: (2019)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders
por: Dalby, Richard N, et al.
Publicado: (2011)

In Vitro Determination of Respimat(®) Dose Delivery in Children: An Evaluation Based on Inhalation Flow Profiles and Mouth–Throat Models
por: Bickmann, Deborah, et al.
Publicado: (2016)

A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
por: Kamin, Wolfgang, et al.
Publicado: (2015)

Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT(®) Re-usable Inhaler
por: Ortsäter, Gustaf, et al.
Publicado: (2019)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
por: Anzueto, Antonio, et al.
Publicado: (2015)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

Patient perceptions of the re-usable Respimat(®) Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
por: Dreher, Michael, et al.
Publicado: (2021)

A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT(®) Re-usable in the Nordics and Benelux
por: Ortsäter, Gustaf, et al.
Publicado: (2019)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat(®) in patients with COPD in a real-world clinical setting
por: Steinmetz, Karl-Otto, et al.
Publicado: (2019)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

Clinical effectiveness of the Respimat(®) inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
por: Ram, Felix SF, et al.
Publicado: (2011)

How to engineer aerosol particle properties and biopharmaceutical performance of propellant inhalers
por: Akhuemokhan, Precious, et al.
Publicado: (2023)

Higher lung deposition with Respimat(®) Soft Mist(™) Inhaler than HFA-MDI in COPD patients with poor technique
por: Brand, Peter, et al.
Publicado: (2008)

Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat
por: Davis, Kimberly H., et al.
Publicado: (2017)

The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis
por: Dhand, Rajiv
Publicado: (2018)

Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports
por: Terry, Paul D., et al.
Publicado: (2020)

Object-oriented simulation: reusability adaptability maintainability
por: Zobrist, George W, et al.
Publicado: (1997)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Assessment of Patient Experiences with Respimat(®) in Everyday Clinical Practice
por: Taube, Christian, et al.
Publicado: (2020)

The 2023 GOLD Report: Updated Guidelines for Inhaled Pharmacological Therapy in Patients with Stable COPD
por: Terry, Paul D., et al.
Publicado: (2023)

A narrative review on trans-nasal pulmonary aerosol delivery
por: Li, Jie, et al.
Publicado: (2020)

Aerosol delivery systems for treating obstructive airway diseases during the SARS-CoV-2 pandemic
por: Lavorini, Federico, et al.
Publicado: (2021)

Reducing carbon footprint by switching to reusable soft-mist inhalers
por: Janson, Christer, et al.
Publicado: (2023)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies
por: Ichinose, Masakazu, et al.
Publicado: (2016)

The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale
por: Wise, Robert A, et al.
Publicado: (2013)

In Vitro Performance Testing of the Novel Medspray® Wet Aerosol Inhaler Based on the Principle of Rayleigh Break-up
por: de Boer, Anne H., et al.
Publicado: (2007)

Comparison of HPMC Inhalation-Grade Capsules and Their Effect on Aerosol Performance Using Budesonide and Rifampicin DPI Formulations
por: Ding, Li, et al.
Publicado: (2022)

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015)

Performance of a novel reusable pediatric pulse oximeter probe
por: King, Carina, et al.
Publicado: (2019)

Disposable versus reusable medical gowns: A performance comparison
por: McQuerry, Meredith, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1fmkget7mvb4nrc2d94ju6g90c